Approval to launch the Phase I Study of repeated and increasing doses to assess CER-209 in NASH/NAFLD
Presentation of CER-209 at the 2nd annual H.C. Wainwright NASH Investor Conference on March 19, 2018
• Regulatory authority approval to begin enrollment in the study
• Daily administration of increasing doses of CER-209 over a 28-day period in patients with a high risk of NAFLD/NASH
• First clinical assessment of the mechanism of action associated with the P2Y13 receptor including liver-related measures of fat accumulation
Toulouse, FRANCE, Lakeland, UNITED STATES, March 7, 2018, 6 pm CET – CERENIS Therapeutics (FR0012616852 – CEREN – PEA-PME eligible), an international biopharmaceutical company dedicated to the discovery and development of HDL-based innovative therapies for treating cardiovascular and metabolic diseases, as well as new HDL-based vectors for targeted drug delivery in the field of oncology, announces the approval and the upcoming launch of the second Phase I study to assess the daily administration of increasing doses of CER-209 over a 28-day period in patients with a high risk of developing Non-Alcoholic Steato-Hepatitis (NASH) and/or Non-Alcoholic Fatty Liver Disease (NAFLD).
Source: Cerenis Therapeutics